Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Express Scripts
Federal Trade Commission
Daiichi Sankyo
Chubb
Moodys
Cerilliant
Citi

Generated: November 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022206

« Back to Dashboard

NDA 022206 describes RAPAFLO, which is a drug marketed by Allergan Sales Llc and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the RAPAFLO profile page.

The generic ingredient in RAPAFLO is silodosin. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the silodosin profile page.
Summary for 022206
Tradename:RAPAFLO
Applicant:Allergan Sales Llc
Ingredient:silodosin
Patents:1
Pharmacology for NDA: 022206
Mechanism of ActionAdrenergic alpha-Antagonists
Suppliers and Packaging for NDA: 022206
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RAPAFLO silodosin CAPSULE;ORAL 022206 NDA Allergan, Inc. 0023-6142 0023-6142-30 30 CAPSULE in 1 BOTTLE, UNIT-DOSE (0023-6142-30)
RAPAFLO silodosin CAPSULE;ORAL 022206 NDA Allergan, Inc. 0023-6142 0023-6142-90 90 CAPSULE in 1 BOTTLE, UNIT-DOSE (0023-6142-90)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength4MG
Approval Date:Oct 8, 2008TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Dec 1, 2018Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength8MG
Approval Date:Oct 8, 2008TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Dec 1, 2018Product Flag?YSubstance Flag?YDelist Request?

Expired US Patents for NDA 022206

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKesson
Merck
Cantor Fitzgerald
Daiichi Sankyo
Queensland Health
Medtronic
Teva
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.